Leerink Partnrs Issues Pessimistic Estimate for BMY Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Research analysts at Leerink Partnrs reduced their Q2 2025 earnings per share estimates for shares of Bristol Myers Squibb in a report released on Wednesday, July 9th. Leerink Partnrs analyst D. Risinger now expects that the biopharmaceutical company will earn $1.09 per share for the quarter, down from their previous forecast of $1.69. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share. Leerink Partnrs also issued estimates for Bristol Myers Squibb’s FY2025 earnings at $6.20 EPS and FY2027 earnings at $6.10 EPS.

BMY has been the topic of several other reports. Wall Street Zen lowered Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 6th. Argus upgraded Bristol Myers Squibb to a “hold” rating in a research note on Friday, April 25th. The Goldman Sachs Group reiterated a “neutral” rating and set a $55.00 price objective (down from $67.00) on shares of Bristol Myers Squibb in a research note on Tuesday, April 8th. Cantor Fitzgerald reiterated a “neutral” rating and set a $55.00 price objective on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. Finally, William Blair reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $57.69.

Bristol Myers Squibb Stock Performance

Shares of Bristol Myers Squibb stock opened at $46.91 on Friday. The business’s fifty day simple moving average is $47.51 and its 200 day simple moving average is $53.28. The firm has a market capitalization of $95.47 billion, a P/E ratio of 17.57, a price-to-earnings-growth ratio of 2.43 and a beta of 0.36. Bristol Myers Squibb has a 12 month low of $39.93 and a 12 month high of $63.33. The company has a current ratio of 1.28, a quick ratio of 1.17 and a debt-to-equity ratio of 2.65.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.50 by $0.30. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The company had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. During the same quarter last year, the company earned ($4.40) earnings per share. The company’s revenue for the quarter was down 5.6% on a year-over-year basis.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be issued a dividend of $0.62 per share. The ex-dividend date is Thursday, July 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.29%. Bristol Myers Squibb’s payout ratio is 92.88%.

Insider Buying and Selling

In related news, EVP Samit Hirawat bought 4,250 shares of the firm’s stock in a transaction that occurred on Friday, April 25th. The shares were bought at an average cost of $47.58 per share, with a total value of $202,215.00. Following the acquisition, the executive vice president owned 83,513 shares in the company, valued at $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.09% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in BMY. Pinney & Scofield Inc. purchased a new position in Bristol Myers Squibb in the fourth quarter worth about $25,000. Park Square Financial Group LLC purchased a new position in Bristol Myers Squibb in the fourth quarter worth about $26,000. Global Wealth Strategies & Associates grew its position in Bristol Myers Squibb by 137.5% in the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 275 shares in the last quarter. Transce3nd LLC purchased a new position in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $28,000. Finally, Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Bristol Myers Squibb during the first quarter valued at approximately $31,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.